文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

在美国大型多样化人群中幽门螺杆菌根除治疗对非贲门胃腺癌发病率的影响

Effect of Helicobacter pylori Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States.
PubMed 文献 · Gastroenterology · 2023-05-02

该回顾性队列研究纳入1997至2015年Kaiser Permanente北加州分会接受幽门螺杆菌检测和/或治疗的716,567人,随访至2018年12月31日。幽门螺杆菌阳性未治疗者较阴性者非贲门胃腺癌风险显著升高(亚分布风险比6.07),治疗者风险亦升高(2.68);治疗者随访≥8年较未治疗者风险降低(亚分布风险比0.37)。

要点

  • 幽门螺杆菌阳性未治疗者非贲门胃腺癌风险约为阴性者的6.07倍。
  • 治疗者随访≥8年较未治疗者非贲门胃腺癌风险降低(亚分布风险比0.37)。
  • 治疗者随访7至10年后非贲门胃腺癌风险低于一般人群。

核心结论

  • 在大型多样化社区人群中,幽门螺杆菌根除治疗与8年后非贲门胃腺癌发病率显著降低相关。
  • 治疗者随访7至10年后风险低于一般人群。
  • 研究结果支持通过幽门螺杆菌根除在美国实现胃癌预防的潜力。

研究设计与样本

  • 回顾性队列研究,纳入1997至2015年Kaiser Permanente北加州分会接受幽门螺杆菌检测和/或治疗的成员,随访至2018年12月31日。
  • 共纳入716,567名有幽门螺杆菌检测和/或治疗史者。
  • 采用Fine-Gray亚分布风险模型和标准化发病率比评估非贲门胃腺癌风险。

主要发现

  • 与幽门螺杆菌阴性者相比,幽门螺杆菌阳性未治疗者非贲门胃腺癌调整亚分布风险比为6.07(95%CI 4.20-8.76)。
  • 与幽门螺杆菌阴性者相比,幽门螺杆菌阳性治疗者非贲门胃腺癌调整亚分布风险比为2.68(95%CI 1.86-3.86)。
  • 直接比较幽门螺杆菌阳性治疗者与阳性未治疗者,随访<8年亚分布风险比为0.95(95%CI 0.47-1.92),随访≥8年为0.37(95%CI 0.14-0.97)。
  • 与Kaiser Permanente北加州一般人群相比,治疗后标准化发病率比随随访时间下降:≥1年2.00(95%CI 1.79-2.24),≥4年1.01(95%CI 0.85-1.19),≥7年0.68(95%CI 0.54-0.85),≥10年0.51(95%CI 0.38-0.68)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High-quality data regarding the effect of Helicobacter pylori eradication on the risk of noncardia gastric adenocarcinoma (NCGA) remain limited in the United States. We investigated the incidence of NCGA after H pylori eradication therapy in a large, community-based US population. METHODS: We performed a retrospective cohort study of Kaiser Permanente Northern California members who underwent testing and/or treatment for H pylori between 1997 and 2015 and were followed through December 31, 2018. The risk of NCGA was evaluated using the Fine-Gray subdistribution hazard model and standardized incidence ratios. RESULTS: Among 716,567 individuals with a history of H pylori testing and/or treatment, the adjusted subdistribution hazard ratios and 95% confidence intervals of NCGA for H pylori-positive/untreated and H pylori-positive/treated individuals were 6.07 (4.20-8.76) and 2.68 (1.86-3.86), respectively, compared with H pylori-negative individuals. When compared directly with H pylori-positive/untreated individuals, subdistribution hazard ratios for NCGA in H pylori-positive/treated were 0.95 (0.47-1.92) at <8 years and 0.37 (0.14-0.97) ≥8 years of follow-up. Compared with the Kaiser Permanente Northern California general population, standardized incidence ratios (95% confidence interval) of NCGA steadily decreased after H pylori treatment: 2.00 (1.79-2.24) ≥1 year, 1.01 (0.85-1.19) ≥4 years, 0.68 (0.54-0.85) ≥7 years, and 0.51 (0.38-0.68) ≥10 years. CONCLUSION: In a large, diverse, community-based population, H pylori eradication therapy was associated with a significantly reduced incidence of NCGA after 8 years compared with no treatment. The risk among treated individuals became lower than the general population after 7 to 10 years of follow-up. The findings support the potential for substantial gastric cancer prevention in the United States through H pylori eradication.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Li D, Jiang SF, Lei NY, et al. Effect of Helicobacter pylori Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States. Gastroenterology. 2023. PMID: 37142201. doi:10.1053/j.gastro.2023.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。